Acute Leukaemia and Myelodysplasia

The ALLG Acute Myeloid Leukaemia (AML)/Acute Lymphoblastic Leukaemia (ALL)/Myelodysplasia Syndrome (MDS) Scientific Working Party is focused currently on developing the following:

  • Increasing the number of Scientific Working Party members involved in acute leukaemia research projects by way of focusing on ALL, AML, and MDS as separate sub-groups
  • Obtaining, developing and operating a greater number of clinical trials across the three disease areas
  • Establishing stronger international cooperative group connections for the Scientific Working Party members to collaborate on more international clinical trials
  • Generating a great number of proposals utilising the NBCR framework
  • For the Scientific Working Party to adopt and/or endorse relevant guidelines or recommendations in AML, ALL and MDS

Stem Cell Transplantation

The Stem Cell Transplanation (SCT) Scientific Working Party is focused currently on developing the following:

  • Increasing participation in the Scientific Working Party meetings to create enthusiasm and generate new research ideas
  • Fostering young investigators and involve Scientific Working Party members who are outside of metropolitan areas
  • Establishing a number of feasible concepts that are ready for funding applications to competitive government grant bodies
  • Expanding international relationships for participation in international clinical trials

Chronic Myeloid Leukaemia and Myeloproliferative Neoplasms

The Chronic Myeloid Leukaemia Scientific Working Party is focused currently on developing the following:

  • Increasing the number investigator-initiated proposals presented to the scientific working party for peer review and endorsement, with the aim of submission to a funding partner
  • Facilitating more publications and presentations in recognised journals and scientific conferences
  • Increasing efforts to facilitate a greater number of data review and low-risk research projects
  • Strengthening membership engagement and broaden representation from all regions across Australia and New Zealand with the promotion of teletrials
  • Encouraging scientific working party members to share emerging research findings for discussion in recent advancements, and plan how the working party can add benefit and value to emerging research
  • Establishing and strengthening relationships with international collaborator and cooperative groups with the aim of collaborating on a clinical trial
  • Developing guidelines for the treatment of CML to improve knowledge of, treatment and access to therapies in Australia and New Zealand
  • In MPN, focusing on the advocacy for promoting new technology in clinical trials via qualitative research projects, and advocate for new technology to be implemented in the health care systems, for example by submission MSAC

Lymphoma

The ALLG Lymphoma Scientific Working Party is focusing its efforts on:

  • Having an open trial in each sub-type of lymphoma for Australian and New Zealand members
  • Emphasising ALLG Membership activity, be it low-risk research, registries or clinical trial activity
  • Increasing the membership of the Lymphoma Scientific Working Party and promote diversity within the Working Party, for example including PET physicians in membership
  • Expanding the relevance of the Scientific Working Party to include education, panel discussions, emerging treatments in overseas health care.
  • Increasing ties and involvement with international trials groups, by the extension of invitation to international trial leaders to visit ALLG
  • Increasing advocacy for new medicines in Australia and New Zealand
  • Considering guidelines and the relationship with lymphoma and its treatment

Chronic Lymphocytic Leukaemia

The ALLG Chronic Lymphocytic Leukaemia (CLL) Scientific Working Party is focused on improving the lives of patients with CLL by:

  • Increasing clinical trial participation at ALLG accredited sites
  • Boosting member engagement and relationships with member sites
  • Supporting new CLL treatment strategies and facilitation of submission to funding partners
  • Strengthening industry partner relationships
  • Supporting cross-discipline proposals including supportive care and laboratory science sub studies
  • Being a world-class leader in CLL clinical trials, education, training and research
  • Training the next generation of CLL researchers with increased participation in Scientific Working Party meetings and trial development
  • Ensuring new trial concepts are patient-centred through engagement of consumers

Myeloma

The ALLG Myeloma Scientific Working Party aims to:

  • Increase opportunities for junior principal investigators to mentored by senior trial leaders
  • Establish research focusing on all areas of myeloma, such as early-phase CT, larger phase III trials, incorporation of translational research, and inclusion of supportive care models, i.e. infection risk, DVT, prevention
  • Work more closely with Myeloma Foundation’s Medical & Scientific Advisory Group (MSAG) for endorsement of relevant guidelines
  • Develop a suite of trials across the continuum of myeloma research i.e. retrospective, real-world, early phase, late phase, correlative research
  • Introduce MRD measurement (flow or NGS) across myeloma trials and to develop a MRD guided clinical trial
  • Collaborate in a study to support the introduction of a new agent onto the PBS
  • Improve the outcome of patients with high-risk myeloma

Laboratory Science

The ALLG Laboratory Scientific Working Party is focused on improving the lives by:

  • Attracting scientists to the Scientific Working Party and retain a good mix of haematologists, clinical researchers and scientists to support translational research across all haematology disciplines
  • Further developing the pathway for members of disease focussed SWPs to seek advice and feedback from lab science members, to further develop and enhance correlative research embedded in clinical trials, and for stand-alone research projects
  • Inviting SWP members and guest speakers to present cutting edge technology and outcomes at SWP meetings to create awareness on innovative methods and, whilst reviewing current projects that may be enhanced with this new information
  • Establishing relationships with international peers and cooperative trial groups by extending invitations to present new research (techniques and outcome) as well establishing connections with international counterparts on ALLG clinical trial correlative research
  • Incorporating new technology to conduct biomarker activities for the members conducting clinical trials
  • Supporting the establishment of a low-risk research process for ALLG members
  • Establishing a database of labs to assist researchers developing projects and establishing connections

Supportive Care

The ALLG Supportive Care Scientific Working Party aims to:

  • In the following two research programs, design, obtain funding for and commence recruitment to a phase III randomised controlled trial:
    • Infection prevention in patients with haematological malignancies
    • Transfusion support in haematological malignancies.
  • Work with the ALLG membership to identify priority areas to develop two new supportive care research programs (e.g. survivorship, fertility preservation, palliative care, nutrition).
  • Leverage existing ALLG clinical trials to incorporate supportive care sub-studies
  • In collaboration with professional societies and other groups, develop Australasian guidelines in priority areas identified by ALLG members.
  • Further develop collaborations with national (e.g. palliative care) and international trial cooperative groups to facilitate ALLG participation in supportive care clinical trials
  • Include consumer involvement in the supportive care research program
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research